Emerald BioStructures and FORMA Therapeutics Enter Strategic Cancer Research Partnership
Published: Jun 28, 2010
BAINBRIDGE ISLAND, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Emerald BioStructures, a leading provider of integrated structural biology services, and FORMA Therapeutics, a drug discovery company, today announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA’s pipeline. This multi-target, multi-year gene-to-structure research partnership will leverage Emerald’s high-throughput X-ray crystallography expertise with FORMA’s proprietary computational platform and Diversity Oriented Synthesis (DOS) chemistry capabilities, to elucidate important cancer targets and optimize the binding of FORMA’S drug candidates. Financial terms of the partnership are not disclosed, but the collaboration will provide funding for multiple full-time employees at Emerald BioStructures.